Pre-earnings options volume in Nuvation Bio (NUVB) is 2.1x normal with calls leading puts 13:1. Implied volatility suggests the market is anticipating a move near 19.2%, or 99c, after results are released. Median move over the past eight quarters is 2.1%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Is NUVB a Buy, Before Earnings?
- Nuvation Bio enrolls first patient in G203 study
- Optimistic Buy Rating for Nuvation Bio Driven by Promising Prospects of Ibtrozi and Safusidenib
- Nuvation Bio enrolls first patient in TRUST-IV Phase 3 study of IBTROZI
- Nuvation Bio’s Strategic Growth Potential and Promising Pipeline Justify Buy Rating